US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Quantum Biopharma Ltd.

15.45

+1.7012.36%

Post-market: 14.95-0.5000-3.24%19:51 EDT

Volume:199.61K

Turnover:2.88M

Market Cap:47.05M

PE:-1.24

High:15.46

Open:14.04

Low:13.75

Close:13.75

Loading ...

Overview Company News Filings

Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari

Quantum Biopharma Chooses BitGo to Store Cryptocurrency Holdings

MT Newswires Live

Press Release: Quantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS), A First-In-Class Treatment for Multiple Sclerosis

Quantum BioPharma Ltd expected to post a loss of 65 cents a share - Earnings Preview

Quantum BioPharma Ltd expected to post a loss of 37 cents a share - Earnings Preview

Quantum Biopharma Files Amended Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Psychedelic: Clearmind completes clinical site initiations for AUD trial

Press Release: Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor

Quantum BioPharma Corporate Update

Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for Ontario

Quantum BioPharma Licensee Celly Nutrition Announces Landmark Partnership with the Asian American Trade Associations Council (AATAC) to Expand Retail Availability of its Alcohol Detox Beverage unbuzzd™

Quantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto Rico

Quantum Biopharma to Jointly Study Demyelination Imaging Technique With Massachusetts Hospital

MT Newswires Live

Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis

Quantum BioPharma Provides Corporate Update

Quantum BioPharma Ltd expected to post a loss of 37 cents a share - Earnings Preview

Quantum Biopharma 2024 Loss Narrows; Shares Jump

MT Newswires Live

Press Release: Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern

Quantum Group appoints Lynch to board of directors

Press Release: Quantum Biopharma Announces Leading Crusader Against Naked Short Selling and Stock Manipulation, Terry Lynch Elected to Board of Directors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/QNTM/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"QNTM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"QNTM\",,,,,undefined,":{"symbol":"QNTM","market":"US","secType":"STK","nameCN":"Quantum Biopharma Ltd.","latestPrice":15.45,"timestamp":1749240000000,"preClose":13.75,"halted":0,"volume":199613,"hourTrading":{"tag":"盘后","latestPrice":14.95,"preClose":15.45,"latestTime":"19:51 EDT","volume":10740,"amount":160984.964,"timestamp":1749253904091},"delay":0,"floatShares":2552300,"shares":3045006,"eps":-12.492258,"marketStatus":"Market Closed","change":1.7,"latestTime":"06-06 16:00:00 EDT","open":14.04,"high":15.46,"low":13.75,"amount":2879329.4956670003,"amplitude":0.124364,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-12.492258,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":13.75,"preHourTrading":{"tag":"盘前","latestPrice":14.2288,"preClose":13.75,"latestTime":"09:29 EDT","volume":2824,"amount":40858.114904,"timestamp":1749216586136},"postHourTrading":{"tag":"盘后","latestPrice":14.95,"preClose":15.45,"latestTime":"19:51 EDT","volume":10740,"amount":160984.964,"timestamp":1749253904091},"volumeRatio":0.6363514063823883},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"QNTM\",,,,,undefined,":{"symbol":"QNTM","floatShares":2552300,"roa":"-71.24%","roe":"-268.81%","lyrEps":-12.492258,"volumeRatio":0.6363514063823883,"shares":3045006,"dividePrice":0,"high":15.46,"amplitude":0.124364,"preClose":13.75,"low":13.75,"week52Low":2.7,"pbRate":"8.21","week52High":23.8095,"institutionHeld":0,"latestPrice":15.45,"eps":-12.492258,"divideRate":0,"volume":199613,"delay":0,"ttmEps":-12.492258,"open":14.04,"prevYearClose":3.68,"prevWeekClose":13.46,"prevMonthClose":13.46,"prevQuarterClose":7.71,"fiveDayClose":13.46,"twentyDayClose":8.74,"sixtyDayClose":4.54},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"QNTM\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540781768","title":"Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari","url":"https://stock-news.laohu8.com/highlight/detail?id=2540781768","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540781768?lang=en_us&edition=fundamental","pubTime":"2025-05-30 19:00","pubTimestamp":1748602800,"startTime":"0","endTime":"0","summary":"Dr. Raza Bokhari, Company’s Former CEO, Paid $2.35 Million USD in Non-Dilutive Cash to Cover Legal and Other Costs Determined in the Arbitral Award Over the Past 4 Years. The agreement brings to a complete and final closure all outstanding issues and prevents any future litigation in various courts in Canada and the United States. The payment of $2,350,000 USD from Dr. Bokhari to Quantum BioPharma Ltd.  satisfies all outstanding monetary claims by the Company, Zeeshan Saeed, Anthony Durkacz and other current or former employees, officers, Directors, affiliates or agents of the Company as well as any and all legal and monetary claims by Dr. Bokhari. The $2,350,000 USD is a non-dilutive injection of cash into Quantum BioPharma.In the agreement, Dr. Raza Bokhari, Quantum BioPharma Ltd, Zeeshan Saeed and Anthony Durkacz did not admit to any wrongdoing. All parties agreed that at all times they were acting in the best interest of the corporation and the shareholders.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/quantum-biopharma-receives-2-35-110000246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USD","USAW.SI","BK4555","MNQmain","TSYW.SI","UN","SQQQ","TQQQ","QNTM","MDCXW","QID","USJW.SI","NVIW.SI",".IXIC","CEO","BK4099","BK4596","QLD","FSD","BK4551","NQmain","BK4007","PSQ","LCID"],"gpt_icon":1},{"id":"2537933340","title":"Quantum Biopharma Chooses BitGo to Store Cryptocurrency Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2537933340","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537933340?lang=en_us&edition=fundamental","pubTime":"2025-05-21 20:47","pubTimestamp":1747831669,"startTime":"0","endTime":"0","summary":"Quantum Biopharma  said Wednesday it has chosen BitGo to manage its cryptocurrency assets, including bitcoin, solana, XRP and dogecoin.Financial terms were not provided.The company said BitGo will provide secure storage and custody services for its digital assets using cold storage and multi-signature wallet technologies.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","QNTM"],"gpt_icon":0},{"id":"2536762611","title":"Press Release: Quantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS), A First-In-Class Treatment for Multiple Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2536762611","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536762611?lang=en_us&edition=fundamental","pubTime":"2025-05-20 19:30","pubTimestamp":1747740600,"startTime":"0","endTime":"0","summary":"TORONTO, May 20, 2025  -- Quantum BioPharma Ltd.    , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces that it has signed an agreement with a global pharmaceutical contract research organization to prepare an IND  application package for Lucid-21-302  with the US FDA. A successful IND application will allow Quantum Biopharma to move forward with a Phase 2 trial of Lucid-21-302 in people with multiple sclerosis .Lucid-21-302 is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action for the treatment of MS. It is a patented New Chemical Entity  that has been shown in preclinical models to prevent demyelination, a known cause of MS and other neurogenerative diseases characterized by damage to the myelin sheath surrounding nerve fibers.\"We are pleased to announce that we have signed this agreement to prepare the IND application package, which we hope to submit to the FDA in ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","BK4099","LU2271345857.HKD","LU1720051108.HKD","LU0971096721.USD","LU1548497426.USD","LU1732800096.USD","LU2111349929.HKD","LCID","LU2089283258.USD","LU0106831901.USD","LU0912757837.SGD","LU0006306889.USD","LU2028103732.USD","BK4534","BK4596","IE00BZ1G4Q59.USD","BK4007","LU2357305700.SGD","LU0158827781.USD","LU0267386448.USD","LU2023251221.USD","IE00BKVL7J92.USD","LU1989772923.USD","BK4555","LU1989772840.SGD","BK4551","LU2133065610.SGD","TM","BK4604","LU2089284900.SGD","LU0106261372.USD","QNTM","BK4516","LU1363072403.SGD","LU0098860793.USD","LU0320765646.SGD","BK4585","LU1668664300.SGD","LU2347655156.SGD","BK4581","LU1162221912.USD","03160","LU0158827948.USD","LU0314104364.USD","LU1720051017.SGD","LU0225283273.USD","BK4504","LU0795875169.SGD","LU0795875086.SGD"],"gpt_icon":0},{"id":"2535087156","title":"Quantum BioPharma Ltd  expected to post a loss of 65 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2535087156","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535087156?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:42","pubTimestamp":1747168923,"startTime":"0","endTime":"0","summary":"Quantum BioPharma Ltd  expected to post a loss of65cents a share - Earnings Preview Quantum BioPharma Ltd QNTM.CD  is expected to report resultson May 15 (estimated) for the period ending March 31 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nL8N3RL2S9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Quantum BioPharma Ltd  expected to post a loss of 65 cents a share - Earnings Preview","news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNTM"],"gpt_icon":0},{"id":"2534466136","title":"Quantum BioPharma Ltd  expected to post a loss of 37 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2534466136","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534466136?lang=en_us&edition=fundamental","pubTime":"2025-05-10 05:36","pubTimestamp":1746826565,"startTime":"0","endTime":"0","summary":"Quantum BioPharma Ltd  expected to post a loss of37cents a share - Earnings Preview Quantum BioPharma Ltd QNTM.CD  is expected to report resultson May 12 (estimated) for the period ending March 31 202","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nL8N3RH3H4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNTM"],"gpt_icon":0},{"id":"2533880315","title":"Quantum Biopharma Files Amended Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing","url":"https://stock-news.laohu8.com/highlight/detail?id=2533880315","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533880315?lang=en_us&edition=fundamental","pubTime":"2025-05-05 19:08","pubTimestamp":1746443280,"startTime":"0","endTime":"0","summary":"To assist enquiries a copy of the amended complaint can be viewed by clicking the following link:Quantum Amended Court Claim. TORONTO, May 05, 2025  -- Quantum BioPharma Ltd.    , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that on May 1, 2025 it filed an amended complaint in the United States District Court for the Southern District of New York. This is an amendment to the original complaint filed on October 21, 2024, is in response to the Motion to Dismiss filed by the banks on January 31, 2025, and is filed in the United States District Court for the Southern District of New York. The amendment and complaint allege that CIBC World Markets , RBC Dominion Securities , and others  engaged in market manipulation schemes that violated Section 10 and Rule 10b-5 and  and Section 9 of the Securities Exchange Act of 1934. This lawsuit alleges that between 1st of January 2020and 15th of August 2024 the Defendants an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/quantum-biopharma-files-amended-complaint-110800965.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LCID","BK4007","BK4596","BK4551","QNTM","BK4099","BK4555","USD","RBC","LU2065731478.USD","IE00BLDYK493.USD","BK4161","IE00B64QTZ34.USD"],"gpt_icon":0},{"id":"2530215933","title":"Psychedelic: Clearmind completes clinical site initiations for AUD trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2530215933","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530215933?lang=en_us&edition=fundamental","pubTime":"2025-04-25 23:30","pubTimestamp":1745595026,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on site initiations, dosing completion and clinical site partnerships.Discover outperforming stocks and invest smarter with Top Smart Score Stocks.Filter, analyze, and streamline your search for investment opportunities using  Tipranks' Stock Screener.“AUD remains one of the most urgent and underserved public health challenges globally,” said Dr. Adi Zuloff-Shani, CEO. “With millions affected and current treatments often falling short, the study initiation for our FDA-approved CMND-100 trial marks a critical step toward potentially transforming the treatment landscape for alcoholism. We are honored to collaborate with world renowned institutions such as Yale and Johns Hopkins as we advance our mission to potentially provide safe, effective, and innovative solutions for individuals those suffering from alcoholism.”“Completing dosing of all participants in Part A of our 005 tria","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AGNPF","RLMD","MIRA","DRUG","BK4547","BETRF","SILO","BK4539","GHRS","CYBN","KTTA","NRXP","IXHL","BK4007","PBM","MNMD","BK4139","SNPX","BK4168","ATAI","ENVB","SPRC","NUMIF","QNTM","ALID","OPTHF","MDXXF","SEEL","PSYGF","MYCOF","BK4202","CMND","ENTBF","PHRRF","RVVTF","FLHLF","CMPS"],"gpt_icon":0},{"id":"2529058371","title":"Press Release: Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor","url":"https://stock-news.laohu8.com/highlight/detail?id=2529058371","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529058371?lang=en_us&edition=fundamental","pubTime":"2025-04-22 19:00","pubTimestamp":1745319600,"startTime":"0","endTime":"0","summary":"Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor. TORONTO, April 22, 2025  -- Quantum BioPharma Ltd.    , is pleased to announce the appointment of Kevin Malone as an advisor to the Board of Directors. Mr. Malone brings a vast wealth of successful stock trading experience, especially in manipulated companies, from his years of wealth management.Mr. Malone is a 2nd generation financial advisor with over 40 years of family experience in wealth management. This combined with his deep entrepreneurial background he launched Malone Wealth in 2021. Mr. Malone focuses deeply on pattern recognition skills and data research to differentiate himself from other financial advisors.Zeeshan Saeed, CEO of Quantum BioPharma said, \"We are thrilled and honored to welcome Kevin Malone as an advisor. His wealth of experience, especially in naked short squeeze strategies, will be an incredible addition to our team of experts fig","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","03160","BK4555","LCID","QNTM","BK4551","BK4588","BK4099","BK4596","BK4585","BK4007","BK4604"],"gpt_icon":1},{"id":"2528041810","title":"Quantum BioPharma Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2528041810","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528041810?lang=en_us&edition=fundamental","pubTime":"2025-04-19 08:00","pubTimestamp":1745020800,"startTime":"0","endTime":"0","summary":"Toronto, Ontario-- - Quantum BioPharma Ltd.     , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announced the following corporate updates.The Company announces the grant of 60,000 restricted share units  pursuant to the Company's equity incentive plan, which are subject to certain vesting criteria. All of the RSUs  are subject to a four month and one day hold period pursuant to the policies of the Canadian Securities Exchange  and applicable securities laws.The Company also announces that the board of directors of the Company  authorized and approved the settlement of outstanding debt owed to arm's length parties by issuing Class B Shares at a deemed price of US$6.75 per Class B Share. The Class B Shares upon issuance will be subject to a four month and one day ho","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/quantum-biopharma-corporate-000000382.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/quantum-biopharma-corporate-000000382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4551","BK4099","LCID","BK4555","QNTM","BK4007","BK4596"],"gpt_icon":0},{"id":"2527615948","title":"Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for Ontario","url":"https://stock-news.laohu8.com/highlight/detail?id=2527615948","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527615948?lang=en_us&edition=fundamental","pubTime":"2025-04-14 19:30","pubTimestamp":1744630200,"startTime":"0","endTime":"0","summary":"Awards in favour of Quantum BioPharma Totalling $180,000 upheld and is now due. TORONTO, April 14, 2025  -- Quantum BioPharma Ltd.     , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announced that the reconsideration motion by Dr. Raza Bokhari at the Court of Appeal for Ontario was dismissed entirely in favour of Quantum BioPharma. Dr. Raza Bokhari, current CEO of Medicus Pharma, Ltd., was CEO of FSD Pharma Inc.   now Quantum BioPharma, in 2019 and was terminated for cause in July 2021.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/quantum-biopharma-wins-reconsideration-motion-113000668.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","LCID","QNTM","BK4596","BK4099","BK4555","BK4551"],"gpt_icon":1},{"id":"2526855774","title":"Quantum BioPharma Licensee Celly Nutrition Announces Landmark Partnership with the Asian American Trade Associations Council (AATAC) to Expand Retail Availability of its Alcohol Detox Beverage unbuzzd™","url":"https://stock-news.laohu8.com/highlight/detail?id=2526855774","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526855774?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:30","pubTimestamp":1744284600,"startTime":"0","endTime":"0","summary":"TORONTO, April  10, 2025  (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), today announced its licensee – Celly Nutrition Corpo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/10/3059144/0/en/Quantum-BioPharma-Licensee-Celly-Nutrition-Announces-Landmark-Partnership-with-the-Asian-American-Trade-Associations-Council-AATAC-to-Expand-Retail-Availability-of-its-Alcohol-Deto.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","LARK","BK4596","QNTM","BK4211","BK4117","BK4099","BK4007","BK4555","LCID","BK4107","AFG"],"gpt_icon":0},{"id":"2524230516","title":"Quantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto Rico","url":"https://stock-news.laohu8.com/highlight/detail?id=2524230516","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524230516?lang=en_us&edition=fundamental","pubTime":"2025-04-03 19:00","pubTimestamp":1743678000,"startTime":"0","endTime":"0","summary":"Alcohol Detoxification and Anti-Hangover Beverage (Available on amazon.com and unbuzzd.com) to be Distributed by FUSION in Puerto Rico and Caribbean Region TORONTO, April  03, 2025  (GLOBE NEWSWIRE) -","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/03/3054974/0/en/Quantum-BioPharma-Licensee-Celly-Nutrition-Launches-unbuzzd-in-Puerto-Rico.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4596","BK4551","QNTM","BK4099","BK4007","BK4555"],"gpt_icon":1},{"id":"2524150713","title":"Quantum Biopharma to Jointly Study Demyelination Imaging Technique With Massachusetts Hospital","url":"https://stock-news.laohu8.com/highlight/detail?id=2524150713","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524150713?lang=en_us&edition=fundamental","pubTime":"2025-04-01 16:23","pubTimestamp":1743495825,"startTime":"0","endTime":"0","summary":"Quantum Biopharma  said Tuesday it entered into a joint clinical study with the Massachusetts General Hospital to investigate an imaging technique to monitor demyelination in people suffering from multiple sclerosis.The parties aims to validate a novel positron emission tomography, or PET, biomarker to monitor myelin integrity and measure demyelination. Multiple sclerosis is a chronic disease of the central nervous system.The financial terms of the collaboration weren't disclosed.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","QNTM"],"gpt_icon":0},{"id":"2524130734","title":"Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2524130734","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524130734?lang=en_us&edition=fundamental","pubTime":"2025-04-01 14:00","pubTimestamp":1743487200,"startTime":"0","endTime":"0","summary":"TORONTO, April  01, 2025  (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/01/3052978/0/en/Quantum-BioPharma-Announces-Joint-Clinical-Study-With-Massachusetts-General-Hospital-Scientists-to-Validate-a-Novel-Positron-Emission-Tomography-PET-Imaging-Technique-to-Monitor-De.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0795875169.SGD","LCID","IE00BZ1G4Q59.USD","LU0225283273.USD","BK4596","LU1720051108.HKD","LU1162221912.USD","BK4192","LU0006306889.USD","LU0267386448.USD","BK4007","LU1720051017.SGD","LU2271345857.HKD","BK4185","LU0912757837.SGD","QNTM","BK4555","LU0098860793.USD","BK4516","LU2133065610.SGD","BK4504","PET","BK4551","LU1074936037.SGD","LU2028103732.USD","LU0320765646.SGD","LU0971096721.USD","LU2111349929.HKD","LU2023251221.USD","LU0795875086.SGD","IE00BKVL7J92.USD","LU1732800096.USD","BK4099","BK4585","LU1732799900.SGD","BK4534","BK4581","JYNT","LU1989772840.SGD","BK4127","LU0106261372.USD","LU2089284900.SGD","LU2347655156.SGD","LU2089283258.USD","LU2357305700.SGD","LU0158827781.USD","LU1989772923.USD","LU1363072403.SGD","BK4588","LU0314104364.USD"],"gpt_icon":0},{"id":"2523463939","title":"Quantum BioPharma Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2523463939","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523463939?lang=en_us&edition=fundamental","pubTime":"2025-03-31 07:00","pubTimestamp":1743375600,"startTime":"0","endTime":"0","summary":"Toronto, Ontario-- - Quantum BioPharma Ltd.    , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced it has renewed the services of King Tide Media LLC based at 806E Windward Way, Suite 816, Lake Worth, Florida for a 1-month term commencing April 1, 2025 for US$15,000 and IR Agency LLC based at 23 Downing Street, Newark NJ 07105, commencing April 1, 2025 for 60 days for US$50,000.This press release contains certain \"forward-looking statements\" within the meaning of applicable Canadian securities law. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance  are not statements of historical fact and may be forward-looking statem","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/quantum-biopharma-provides-corporate-230000648.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/quantum-biopharma-provides-corporate-230000648.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4551","BK4007","QNTM","BK4099","BK4555","BK4596","LCID"],"gpt_icon":0},{"id":"2523490680","title":"Quantum BioPharma Ltd  expected to post a loss of 37 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2523490680","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523490680?lang=en_us&edition=fundamental","pubTime":"2025-03-29 04:13","pubTimestamp":1743192791,"startTime":"0","endTime":"0","summary":"Quantum BioPharma Ltd  expected to post a loss of37cents a share - Earnings Preview Quantum BioPharma Ltd QNTM.CD  is expected to report resultson March 28 for the period ending March 31 2025The Toron","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL5N3QB1QS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNTM"],"gpt_icon":0},{"id":"2522189501","title":"Quantum Biopharma 2024 Loss Narrows; Shares Jump","url":"https://stock-news.laohu8.com/highlight/detail?id=2522189501","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522189501?lang=en_us&edition=fundamental","pubTime":"2025-03-28 23:08","pubTimestamp":1743174512,"startTime":"0","endTime":"0","summary":"Quantum Biopharma  reported a 2024 net loss of $14.9 million, narrowing from the loss of $18.2 million a year earlier.Cash and cash equivalents were $12.1 million as of December 31, compared with $11.1 million a year earlier, the company said Friday in a statement.A \"strong balance sheet and overall progress\" enabled the company to remove its \"material uncertainty related to going concern\" designation, according to the statement. \"Management believes there is sufficient cash on hand to sustain basic operations beyond January 2027.\"The company's shares jumped 35% in recent Friday trading.Price: 11.28, Change: +2.90, Percent Change: +34.59","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["QNTM","BK4007"],"gpt_icon":0},{"id":"2522543762","title":"Press Release: Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern","url":"https://stock-news.laohu8.com/highlight/detail?id=2522543762","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522543762?lang=en_us&edition=fundamental","pubTime":"2025-03-28 16:30","pubTimestamp":1743150600,"startTime":"0","endTime":"0","summary":"Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern. Completion of unbuzzd Clinical Trial and Multiple Sclerosis Drug Lucid-21-302 Phase 1 Trial Advance Company's Pipeline of Products and Assets. TORONTO, March 28, 2025  -- Quantum BioPharma Ltd.    , has reported its financial and operational results for the fourth quarter and year ended December 31, 2024.Fourth Quarter and Full Year 2024 Financial Results. The company's strong balance sheet and overall progress enabled it to remove its Material Uncertainty Related to Going Concern. Management is confident that there is sufficient working capital as of December 31, 2024 to carry out its operations over the next twelve months. Management believes there is sufficient cash on hand to sustain basic operations beyond January 2027.For the year ended December 31, 2024, Operating Expenses were reduced to $16.1 mil","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNTM"],"gpt_icon":1},{"id":"2522002376","title":"Quantum Group appoints Lynch to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522002376","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522002376?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:20","pubTimestamp":1743074418,"startTime":"0","endTime":"0","summary":"Quantum BioPharma (QNTM) announces the appointment of Terry Lynch to its board of directors. Lynch will be replacing Dr. Sanjiv Chopra, who has res...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quantum-group-appoints-lynch-to-board-of-directors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quantum-group-appoints-lynch-to-board-of-directors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QNTM","BK4007"],"gpt_icon":0},{"id":"2522375550","title":"Press Release: Quantum Biopharma Announces Leading Crusader Against Naked Short Selling and Stock Manipulation, Terry Lynch Elected to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522375550","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522375550?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:00","pubTimestamp":1743073200,"startTime":"0","endTime":"0","summary":"Quantum Biopharma Announces Leading Crusader Against Naked Short Selling and Stock Manipulation, Terry Lynch Elected to Board of Directors. TORONTO, March 27, 2025  -- Quantum BioPharma Ltd.    , is pleased to announce the appointment of Terry Lynch to its board of directors. Mr. Lynch will be replacing Dr. Sanjiv Chopra, who has resigned from his position on the board. The Company thanks Dr. Chopra for his contribution so far. Dr. Chopra will continue to serve as an advisor to the company.Quantum BioPharma  is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcoh","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4007","QNTM","03160","BK4588","LCID","BK4099","BK4551","BK4596","BK4585","BK4604","TM"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":50,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/QNTM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-08-15","symbol":"QNTM","defaultRemindTime":1723728600000,"type":"split","dateTimestamp":1723694400000,"forFactor":65,"toFactor":1,"ratio":65},{"market":"US","date":"2024-08-14","symbol":"QNTM","fiscalQuarterEnding":"2024/06","expectedEps":-0.06,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"pre","actualEps":-0.08},{"market":"US","date":"2024-05-14","symbol":"QNTM","fiscalQuarterEnding":"2024/03","expectedEps":-0.05,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715659200000,"reportTimeType":"post","actualEps":-0.05},{"market":"US","date":"2024-03-28","symbol":"QNTM","fiscalQuarterEnding":"2023/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1711598400000,"reportTimeType":"post","actualEps":-0.04},{"market":"US","date":"2023-11-14","symbol":"QNTM","fiscalQuarterEnding":"2023/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1699938000000,"reportTimeType":"post","actualEps":-0.03}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"QNTM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"QNTM\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1745899200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/QNTM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"QNTM","date":"2025-06-06","current":-1.987659,"percent":0.04,"low":-2.690643,"twenty":-1.412213,"median":-1.024718,"eighty":-0.730988,"high":-0.546516,"avg":-1.108285,"sd":0.421851,"marketCap":41494516.93},"quantilePoints":[{"date":"2024-08-16","current":-0.603659,"twenty":-0.603659,"median":-0.603659,"eighty":-0.603659,"marketCap":4509122.69},{"date":"2024-08-23","current":-0.69618,"twenty":-0.715087,"median":-0.702389,"eighty":-0.647248,"marketCap":5200216.8},{"date":"2024-08-30","current":-0.852638,"twenty":-0.775012,"median":-0.723053,"eighty":-0.69618,"marketCap":6368904.17},{"date":"2024-09-06","current":-0.700453,"twenty":-0.779153,"median":-0.715087,"eighty":-0.653758,"marketCap":5232131.53},{"date":"2024-09-13","current":-0.690425,"twenty":-0.744955,"median":-0.704525,"eighty":-0.66483,"marketCap":5157233.86},{"date":"2024-09-20","current":-0.993485,"twenty":-0.779153,"median":-0.708429,"eighty":-0.669437,"marketCap":7420982.26},{"date":"2024-09-27","current":-0.939399,"twenty":-0.944216,"median":-0.716816,"eighty":-0.671749,"marketCap":7016975.73},{"date":"2024-10-04","current":-0.974979,"twenty":-0.964556,"median":-0.73591,"eighty":-0.672431,"marketCap":7282751.47},{"date":"2024-10-11","current":-1.090369,"twenty":-0.996068,"median":-0.785363,"eighty":-0.686838,"marketCap":8144673.49},{"date":"2024-10-18","current":-1.45785,"twenty":-1.05098,"median":-0.878475,"eighty":-0.692178,"marketCap":10889624.45},{"date":"2024-10-25","current":-1.442036,"twenty":-1.139524,"median":-0.944288,"eighty":-0.695467,"marketCap":10771499.96},{"date":"2024-10-31","current":-1.205452,"twenty":-1.188827,"median":-0.956387,"eighty":-0.698744,"marketCap":9004299.96},{"date":"2024-11-08","current":-1.349307,"twenty":-1.226202,"median":-0.974979,"eighty":-0.705239,"marketCap":10078847.03},{"date":"2024-11-15","current":-0.935735,"twenty":-1.275577,"median":-0.971909,"eighty":-0.70853,"marketCap":9579098.88},{"date":"2024-11-22","current":-0.960529,"twenty":-1.226202,"median":-0.963485,"eighty":-0.712491,"marketCap":9832911.8},{"date":"2024-11-29","current":-0.869873,"twenty":-1.213599,"median":-0.963485,"eighty":-0.716471,"marketCap":8904877.06},{"date":"2024-12-06","current":-0.815226,"twenty":-1.195279,"median":-0.949234,"eighty":-0.720349,"marketCap":8345447.87},{"date":"2024-12-13","current":-0.759973,"twenty":-1.179109,"median":-0.943869,"eighty":-0.728196,"marketCap":7779827.58},{"date":"2024-12-20","current":-0.685739,"twenty":-1.175332,"median":-0.939333,"eighty":-0.720349,"marketCap":7019890.91},{"date":"2024-12-27","current":-0.616825,"twenty":-1.165719,"median":-0.934788,"eighty":-0.708463,"marketCap":6314424.32},{"date":"2025-01-03","current":-0.759721,"twenty":-1.141743,"median":-0.927085,"eighty":-0.708429,"marketCap":7777249.84},{"date":"2025-01-10","current":-0.742133,"twenty":-1.141141,"median":-0.878991,"eighty":-0.708564,"marketCap":7597197.4},{"date":"2025-01-17","current":-0.619978,"twenty":-1.139524,"median":-0.852638,"eighty":-0.692178,"marketCap":6346706.26},{"date":"2025-01-24","current":-0.619485,"twenty":-1.109884,"median":-0.815226,"eighty":-0.676014,"marketCap":6341654.9},{"date":"2025-01-31","current":-0.561714,"twenty":-1.082749,"median":-0.80554,"eighty":-0.668876,"marketCap":5750259.21},{"date":"2025-02-07","current":-2.690643,"twenty":-1.13989,"median":-0.808855,"eighty":-0.664161,"marketCap":27544054.02},{"date":"2025-02-14","current":-1.986183,"twenty":-1.178654,"median":-0.820792,"eighty":-0.668876,"marketCap":20332510.29},{"date":"2025-02-21","current":-1.288506,"twenty":-1.229787,"median":-0.861255,"eighty":-0.670874,"marketCap":13190405.23},{"date":"2025-02-28","current":-0.926203,"twenty":-1.213599,"median":-0.879508,"eighty":-0.672308,"marketCap":9481520.11},{"date":"2025-03-07","current":-0.836122,"twenty":-1.195279,"median":-0.874174,"eighty":-0.673618,"marketCap":8559365.07},{"date":"2025-03-14","current":-0.835912,"twenty":-1.179109,"median":-0.852638,"eighty":-0.675778,"marketCap":8557218.89},{"date":"2025-03-21","current":-1.273806,"twenty":-1.21489,"median":-0.874174,"eighty":-0.680186,"marketCap":13039931.07},{"date":"2025-03-28","current":-1.564993,"twenty":-1.229787,"median":-0.90884,"eighty":-0.687613,"marketCap":16020800.96},{"date":"2025-04-04","current":-1.52667,"twenty":-1.237788,"median":-0.92592,"eighty":-0.691301,"marketCap":21682873.03},{"date":"2025-04-11","current":-1.273742,"twenty":-1.263262,"median":-0.933841,"eighty":-0.694042,"marketCap":18090602.39},{"date":"2025-04-17","current":-1.168311,"twenty":-1.270743,"median":-0.939267,"eighty":-0.697035,"marketCap":16593197.2},{"date":"2025-04-25","current":-1.303484,"twenty":-1.273793,"median":-0.943051,"eighty":-0.702048,"marketCap":18513021.69},{"date":"2025-05-02","current":-1.294143,"twenty":-1.300404,"median":-0.949177,"eighty":-0.708463,"marketCap":18380352.73},{"date":"2025-05-09","current":-1.644919,"twenty":-1.308736,"median":-0.962007,"eighty":-0.709896,"marketCap":23362327.89},{"date":"2025-05-16","current":-1.199271,"twenty":-1.337538,"median":-0.972354,"eighty":-0.715779,"marketCap":25036080.26},{"date":"2025-05-23","current":-1.700878,"twenty":-1.355009,"median":-0.987733,"eighty":-0.719447,"marketCap":35507635.07},{"date":"2025-05-30","current":-1.849192,"twenty":-1.384044,"median":-0.999942,"eighty":-0.723053,"marketCap":38603856.21},{"date":"2025-06-06","current":-1.987659,"twenty":-1.412213,"median":-1.024718,"eighty":-0.730988,"marketCap":41494516.93}],"updateTime":1749372445707}}}